Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bullock

Showing results (101-110 of 220) with videos related to

Pageof 22
Sort By:
ACS Chemical Biology|April 4, 2013
Development of an ALK2-biased BMP type I receptor kinase inhibitorAgustin H Mohedas, Xuechao Xing, Kelli A Armstrong, et al.
Angiogenesis|January 6, 2015
A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesisGeorgina Kerr, Helen Sheldon, Apirat Chaikuad, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, et al.
Angewandte Chemie (International Ed. in English)|December 29, 2005
Ruthenium half-sandwich complexes bound to protein kinase Pim-1Judit E Debreczeni, Alex N Bullock, G Ekin Atilla, et al.
The American Journal of Surgical Pathology|March 19, 2021
MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint InhibitorsAnna C Dusenbery, Joseph L Maniaci, Natalie D Hillerson, et al.
The American Journal of Surgical Pathology|June 5, 2020
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint InhibitionMegan E Dibbern, Timothy N Bullock, Taylor M Jenkins, et al.
Journal of Medicinal Chemistry|August 8, 2018
Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of ConceptLiam Hudson, James Mui, Santiago Vázquez, et al.
Biomedicines|March 6, 2021
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaFrancesc Ventura, Eleanor Williams, Makoto Ikeya, et al.
British Journal of Urology|October 1, 1996
A review of antegrade stenting in the management of the obstructed kidneyS D Sharma, R A Persad, A Haq, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinasesOleg Fedorov, Brian Marsden, Vanda Pogacic, et al.
Pageof 22

Showing results (101-110 of 220) with videos related to

Sort By:
Pageof 22
ACS Chemical Biology|April 4, 2013
Development of an ALK2-biased BMP type I receptor kinase inhibitorAgustin H Mohedas, Xuechao Xing, Kelli A Armstrong, et al.
Angiogenesis|January 6, 2015
A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesisGeorgina Kerr, Helen Sheldon, Apirat Chaikuad, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, et al.
Angewandte Chemie (International Ed. in English)|December 29, 2005
Ruthenium half-sandwich complexes bound to protein kinase Pim-1Judit E Debreczeni, Alex N Bullock, G Ekin Atilla, et al.
The American Journal of Surgical Pathology|March 19, 2021
MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint InhibitorsAnna C Dusenbery, Joseph L Maniaci, Natalie D Hillerson, et al.
The American Journal of Surgical Pathology|June 5, 2020
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint InhibitionMegan E Dibbern, Timothy N Bullock, Taylor M Jenkins, et al.
Journal of Medicinal Chemistry|August 8, 2018
Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of ConceptLiam Hudson, James Mui, Santiago Vázquez, et al.
Biomedicines|March 6, 2021
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaFrancesc Ventura, Eleanor Williams, Makoto Ikeya, et al.
British Journal of Urology|October 1, 1996
A review of antegrade stenting in the management of the obstructed kidneyS D Sharma, R A Persad, A Haq, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinasesOleg Fedorov, Brian Marsden, Vanda Pogacic, et al.
Pageof 22